Hims & Hers Upgrade: Regulatory Relief on Peptides Plus Operational Discipline Makes a Buy

Hook and thesis
A recent regulatory development that appears to clear the way for Hims & Hers to sell or distribute therapeutic peptides has removed a major overhang for the stock. Combine that with evidence management is prioritizing margin repair and capital discipline after aggressive growth spending, and you have a plausible path for HIMS to re-rate higher from current levels.

I'm upgrading Hims & Hers to a Buy. The trigger is two-fold: (1) regulatory noise around peptides is now trending positive, which re-opens a higher-margin product lane; and (2) the company’s revenue base and guidance remain intact even as management absorbs short-term margin pain to fund international expansion and product diversification. These factors, together with heavy short interest and already significant market attention, create an actionable trade with a clear entry, stop and target and a long-term (180 trading days) horizon.

What the company does and why the market should care

Hims & Hers Health, Inc. operates a direct-to-consumer telehealth platform connecting consumers to clinical care across mental health, sexual health, dermatology, primary care and weight-loss/GLP-1 therapies. The business is attractive because it combines digital distribution with recurring prescription demand and a low-touch care model that scales better than brick-and-mortar peers.

Why investors should care now: Hims sits at the intersection of two secular trends. First, employer plan shifts and payer dynamics are pushing some volume toward DTC telehealth providers for controlled therapies, particularly as employers pivot on GLP-1 coverage. Second, regulatory clarity on peptides would reopen an addressable market that carries better gross margins than the branded weight-loss SKUs Hims has leaned into recently. If those two forces play out as they currently appear to be, revenue growth can stay positive while margins recover over the medium term.

Hard numbers to anchor the view

Those figures matter. Revenue is still growing, at $608.1 million in Q1 2026 (up 4% y/y), and management raised full-year revenue guidance to $2.8-3.0 billion. But profitability is the cautionary flag: the company swung to a $92.1 million net loss in the quarter and reported meaningful adjusted EBITDA compression and gross-margin decline as it shifted mix toward lower-margin branded weight-loss products and funded expansion initiatives.

Valuation framing

At a market cap roughly in the low-to-mid $6 billion range and enterprise value near $8.3 billion, Hims is priced at about 3.2x price-to-sales and above-average trailing multiples for digital telehealth assets given its negative earnings. EV/EBITDA sits very high (reported near 222x), reflecting the current trough in profitability. That multiple structure implies the market is pricing in continued margin pressure or execution risk.

My view: those multiples look stretched on current results but become reasonable if (a) the peptide regulatory risk is removed and peptide sales reintroduce higher gross margins; and (b) the company demonstrates a return-to-normalized adjusted EBITDA margin closer to prior levels as product mix stabilizes. In short, this is a trade that depends on re-acceleration of margin, not just revenue.

Catalysts (what will move the stock)

• Regulatory clarity / court ruling on therapeutic peptides - a confirmed positive outcome meaningfully re-expands higher-margin product options.
• Q3 / Q4 earnings cadence that shows margin stabilization or sequential adjusted EBITDA improvement versus Q1's large drop.
• Early integration signs and revenue contribution from the Eucalyptus acquisition – evidence of international revenue diversification.
• Employer benefit shifts that funnel GLP-1 demand into DTC channels in 2027, supporting recurring prescription volumes.
• Any buyback, convertible-note repricing or steps to reduce leverage that reduce dilution/capital risk.

Trade plan - actionable entry, stop, target and horizon

Entry: Buy at $29.18 (current market price).
Stop: $23.00.
Target: $45.00.
Time horizon: long term (180 trading days) - expect to hold the position for roughly three to six months, allowing time for the peptide ruling to translate into product rollout or regulatory details, and for management's margin actions to begin showing up in the P&L.

Why these levels? Entry at $29.18 captures the stock after a sharp pullback from short-term highs while keeping risk defined. A stop at $23.00 sits under recent technical support and gives room for volatility but limits downside to a meaningful and measurable loss. The $45.00 target reflects an upside scenario where peptide revenue prints, adjusted EBITDA begins to recover toward mid-cycle levels, and multiple expansion from the current depressed EV/EBITDA compresses toward more normalized SaaS/DTC multiples. That target implies roughly 54% upside from entry and is conservative relative to the 52-week high of $70.43 observed last year.

Position sizing and execution notes
Given HIMS’ high short interest and outsized intraday volume, scale into the position. Use limit orders near the entry and consider a two-tranche approach: half at $29.18 and half on a disciplined pullback to the low-$20s if it shows support near the stop. Maintain tight risk control and size the position so that a stop-fill at $23.00 limits portfolio loss to an acceptable percentage.

Risks and counterarguments

• Regulatory reversal or delayed implementation: The core bull case assumes the peptide ruling remains favorable and the company can actually commercialize peptide therapies. Any reversal or lengthy rollout materially damages the thesis.
• Margin compression persists: Management signaled lower adjusted EBITDA guidance and Q1 gross margin fell from 73% to 65%. If the shift to lower-margin branded weight-loss products continues, margins could stay depressed and multiples will compress further.
• Convertible debt and dilution risk: The company issued $350M of zero-coupon convertible debt tied to the Eucalyptus acquisition. That instrument either dilutes shareholders if converted or burdens cash flow if redeemed, and it keeps leverage and dilution in play.
• Legal and privacy overhangs: Recent investigations into alleged user-data tracking could lead to reputational damage, fines or higher compliance costs that erode margins.
• High short interest and price volatility: A large short base (short interest north of 30% at times) can produce rapid downside on negative headlines and amplify volatility around earnings and regulatory updates.

Counterargument: The stock has already rallied strongly this year and a sizable portion of good news may be priced in; Wall Street remains cautious with only a handful of buy ratings. If macro or sector sentiment turns negative or if management fails to show rapid margin repair, downside from here can be steep and quick.

What would change my mind

I will downgrade this trade if any of the following happens: a materially adverse regulatory decision on peptides; continued and accelerating adjusted EBITDA deterioration without a credible plan to stop the bleed; or a capital action that meaningfully dilutes shareholders beyond current expectations (for example, a large equity raise at depressed prices). Conversely, I will add to the position or move the target higher if we see sustained sequential margin improvement, initial peptide revenue that shows superior gross margins, or clear evidence the Eucalyptus acquisition is contributing to revenue diversification.

Bottom line
Hims & Hers is a high-conviction trade at current levels for investors who accept volatility and execution risk. Regulatory clarity on peptides combined with management discipline would unlock a path back to healthier margins and justify expansion from current valuation levels. Keep the trade horizon to long term (180 trading days), size positions carefully, and use the $23 stop to limit downside while letting fundamental improvement drive upside toward the $45 target.